Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 29, 2016. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Transaction Price: $43.12 per American Depositary Share (ADS).
- Transaction Type: Acquisition of ADSs via dividend reinvestment.
- Dividend Date: April 14, 2016.
Material Changes
The filing details specific changes in shareholdings for the following individuals resulting from the dividend reinvestment plan:
- Dr M M Slaoui: Acquired 972.441 ADSs.
- Mr N Hirons: Acquired 531.272 ADSs.
- Mr D E Troy: Acquired 2,802.547 ADSs.
- Dr K Slaoui (Connected Person): Acquired 16.856 ADSs.
GSK was informed of these allocations on April 28, 2016.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity and contains no forward-looking financial statements.
Investor Verification Checklist
- Verify the total number of ADSs acquired by each listed Director and PDMR.
- Confirm the transaction price of $43.12 per ADS aligns with market prices on the transaction date.
- Ensure the dividend reinvestment mechanism was applied correctly for the April 14, 2016 dividend.
- Check for any subsequent filings regarding the same individuals for the same period.